Sedat Üstündağ1, Ekrem Doğan2, Murat Duranay3, Rümeyza Kazancıoğlu4, Vedat Çelik5, Abdülkadir Ünsal6, Lütfullah Altıntepe7, Belda Dursun8, Ertuğrul Akbaş9, Fatih Özdener9, Alaattin Yıldız10. 1. Department of Internal Medicine, Division of Nephrology, Trakya University School of Medicine, Edirne, Turkey. 2. Selahaddin Eyyubi University Faculty of Health Sciences, Diyarbakır, Turkey. 3. Clinic of Nephrology, Ankara Training and Research Hospital, Ankara, Turkey. 4. Clinic of Nephrology, Haseki Training and Research Hospital, İstanbul, Turkey. 5. Clinic of Nephrology, Okmeydanı Training and Research Hospital, İstanbul, Turkey. 6. Clinic of Nephrology, Sişli Etfal Training and Research Hospital, İstanbul, Turkey. 7. Clinic of Nephrology, Konya Training and Research Hospital, Konya, Turkey. 8. Department of Internal Medicine, Division of Nephrology, Pamukkale University School of Medicine, Denizli, Turkey. 9. Roche Pharmaceuticals, İstanbul, Turkey. 10. Department of Internal Medicine, Division of Nephrology, İstanbul University İstanbul School of Medicine, İstanbul, Turkey.
Abstract
BACKGROUND: We investigated the efficacy, safety and tolerability of once-monthly administration of C.E.R.A. in erythropoiesis stimulating agents (ESAs) naive predialysis patients with CKD for anemia treatment. STUDY DESIGN: Single arm, open label study. METHODS: A total of 75 patients (mean (SD) age was 52.8 (16.4) years, 76.0% were female) were included in this study conducted between 12 August 2008 and 30 October 2009 in 9 centers across Turkey. The mean change in Hb concentration (g/dL) between baseline (week 0) and the efficacy evaluation period (EEP) was the primary efficacy parameter evaluated in three consecutive periods including a dose titration period (DTP; with initial 1.2 μg/kg dose of C.E.R.A., subcutaneously, 28 weeks), EEP (8 weeks) and a long-term safety period (16 weeks). RESULTS: Our analysis revealed an improvement in Hb levels from baseline value of 9.4 (0.4) g/dL to time adjusted average level of 11.4 (0.7) g/dL in EEP in the per protocol (PP) population and from 9.3 (0.5) g/dL to 11.1 (1.0) g/dL in intent-to-treat (ITT) population. Mean (SD) change in Hb levels from baseline to EEP was 2.0 (0.7) g/dl in the PP population (primary endpoint) and 1.7 (1.1) g/dL in the ITT population. The percentage of patients whose Hb concentrations remained within the target range of 10.0-12.0 g/dL throughout the EEP was 43.9% (95% CI: 28.5-60.3%) in the PP population and 38.7% (95% CI: 27.6% to 50.6%) in the ITP population. A total of 206 adverse events (AE) were reported in 77.0% of patients with hypertension (20%) as the most frequent AE. CONCLUSION: Once-monthly subcutaneous C.E.R.A. administration is effective and safe in the treatment of anemia in pre-dialysis patients with CKD, who are not currently treated with ESAs.
BACKGROUND: We investigated the efficacy, safety and tolerability of once-monthly administration of C.E.R.A. in erythropoiesis stimulating agents (ESAs) naive predialysis patients with CKD for anemia treatment. STUDY DESIGN: Single arm, open label study. METHODS: A total of 75 patients (mean (SD) age was 52.8 (16.4) years, 76.0% were female) were included in this study conducted between 12 August 2008 and 30 October 2009 in 9 centers across Turkey. The mean change in Hb concentration (g/dL) between baseline (week 0) and the efficacy evaluation period (EEP) was the primary efficacy parameter evaluated in three consecutive periods including a dose titration period (DTP; with initial 1.2 μg/kg dose of C.E.R.A., subcutaneously, 28 weeks), EEP (8 weeks) and a long-term safety period (16 weeks). RESULTS: Our analysis revealed an improvement in Hb levels from baseline value of 9.4 (0.4) g/dL to time adjusted average level of 11.4 (0.7) g/dL in EEP in the per protocol (PP) population and from 9.3 (0.5) g/dL to 11.1 (1.0) g/dL in intent-to-treat (ITT) population. Mean (SD) change in Hb levels from baseline to EEP was 2.0 (0.7) g/dl in the PP population (primary endpoint) and 1.7 (1.1) g/dL in the ITT population. The percentage of patients whose Hb concentrations remained within the target range of 10.0-12.0 g/dL throughout the EEP was 43.9% (95% CI: 28.5-60.3%) in the PP population and 38.7% (95% CI: 27.6% to 50.6%) in the ITP population. A total of 206 adverse events (AE) were reported in 77.0% of patients with hypertension (20%) as the most frequent AE. CONCLUSION: Once-monthly subcutaneous C.E.R.A. administration is effective and safe in the treatment of anemia in pre-dialysis patients with CKD, who are not currently treated with ESAs.
Authors: C Esposito; M Abelli; G Sileno; C Migotto; M Torreggiani; N Serpieri; N Maggi; V Esposito; F Grosjean; M L Scaramuzzi; F Montagna; A D Canton Journal: Transplant Proc Date: 2012-09 Impact factor: 1.066
Authors: Nathan W Levin; Steven Fishbane; Francisco Valdés Cañedo; Steven Zeig; George M Nassar; John E Moran; Giuseppe Villa; Ulrich Beyer; Delphine Oguey Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Michèle Kessler; Alberto Martínez-Castelao; Kostas C Siamopoulos; Giuseppe Villa; Bruce Spinowitz; Frank C Dougherty; Ulrich Beyer Journal: Hemodial Int Date: 2009-11-03 Impact factor: 1.812
Authors: Francesco Locatelli; Giuseppe Villa; Angel L M de Francisco; Alberto Albertazzi; Horacio J Adrogue; Frank C Dougherty; Ulrich Beyer Journal: Curr Med Res Opin Date: 2007-05 Impact factor: 2.580
Authors: Simon D Roger; Francesco Locatelli; Rainer P Woitas; Maurice Laville; Sheldon W Tobe; Robert Provenzano; Thomas A Golper; Prajej Ruangkanchanasetr; Ho Yung Lee; Kwan-Dun Wu; Michal Nowicki; Agnes Ladanyi; Alberto Martínez-Castelao; Ulrich Beyer; Frank C Dougherty Journal: Nephrol Dial Transplant Date: 2011-04-19 Impact factor: 5.992